Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 140 clinical trials
None
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or

paclitaxel
epidermal growth factor receptor
progesterone
mammogram
metastasis
  • 0 views
  • 26 Sep, 2021
None
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2

cish
measurable disease
PIK3CA
HER2
aromatase inhibitor
  • 0 views
  • 26 Apr, 2021
  • 8 locations
None
CB-103 Plus NSAI In Luminal Advanced Breast Cancer

-steroidal aromatase inhibitor (NSAI), anastrozole or letrozole, in Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer patients who have achieved

  • 0 views
  • 29 Apr, 2021
  • 15 locations
None
Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma

improving significantly the overall survival of patients notably anti-HER molecules. In inoperable recurrent and/or metastatic HNSCC, the best treatment is based on an anti-Human Epidermal Growth Factor

  • 1 views
  • 08 Nov, 2020
None
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

epidermal growth factor receptor 2 (-) in combined with Exemestane period , including confirmation of the maximum tolerated dose(MTD) of the combined therapy with Exemestane.

lxi-15029
epidermal growth factor receptor
measurable disease
tumor cells
erbb2
  • 18 views
  • 26 Jan, 2021
  • 1 location
None
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

advanced or metastatic hormonal receptor positive (HR+)/ Human epidermal growth factor receptor 2 (HER2) negative breast cancer. All the patients will be included in the final tolerability and preliminary

  • 2 views
  • 13 May, 2021
  • 1 location
None
TAC T-cells for the Treatment of HER2-positive Solid Tumors

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2

  • 0 views
  • 21 Oct, 2021
  • 4 locations
None
A First in Human Study of BAY2701439 to Look at Safety How the Body Absorbs Distributes and Excretes the Drug and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

In this study, researchers want to learn about the safety of drug BAY2701439 and how well the drug works in patients with advanced cancer that has the protein HER2 (Human Epidermal growth factor

  • 0 views
  • 08 Oct, 2021
  • 6 locations
None
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma

Some cancers of the oesophagus and stomach express excessive copies of either the cMYC (Myelocytomatosis oncogene) gene, the HER2 (Human epidermal growth factor receptor 2) gene or both. These

  • 50 views
  • 23 Jan, 2021
  • 1 location
None
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Multi-center, non randomised, open label, non controlled pilot study. Evaluating the treatment of bevacizumab in association with pre-operative chemotherapy, followed by surgery, adjuvant chemotherapy and radiotherapy in Patients with inflammatory breast cancer.

metastasis
trastuzumab
cyclophosphamide
epirubicin
ejection fraction
  • 13 views
  • 07 Nov, 2020
  • 1 location